m+Medelevator.RU
← Поиск публикаций
BMC cancer · 2010

Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study.

СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Kim Hyo Song, Kim Eun Kyoung, Jun Hyun Jung, Oh Sung Yong, Park Keon Woo, Lim Do Hyoung, Lee Soon Il, Kim Jung Han, Kim Kyoung Mee, Lee Dae Ho, Lee Jeeyun

Аннотация

BACKGROUND: We performed multicenter study to define clinical characteristics of noncutaneous melanomas and to establish prognostic factors patients who received curative resection.

METHODS: Of the 141 patients who were diagnosed of non-cutaneous melanoma at 4 institutions in Korea between June 1992 and May 2005, 129 (91.5%) satisfied the selection criteria.

RESULTS: Of the 129 noncutaneous melanoma patients, 14 patients had ocular melanoma and 115 patients had mucosal melanoma. For mucosal melanoma, anorectum was the most common anatomic site (n=39, 30.2%) which was followed by nasal cavity (n=30, 23.3%), genitourinary (n=21, 16.3%), oral cavity (n=14, 10.9%), upper gastrointestinal tract (n=6, 4.7%) and maxillary sinus (n=5, 3.9%) in the order of frequency. With the median 64.5 (range 4.3-213.0) months follow-up, the median overall survival were 24.4 months (95% CI 13.2-35.5) for all patients, and 34.6 (95% CI 24.5-44.7) months for curatively resected mucosal melanoma patients. Adverse prognostic factors of survival for 87 curatively resected mucosal melanoma patients were complete resection (R1 resection margin), and age>50 years. For 14 ocular melanoma, Survival outcome was much better than mucosal melanoma with 73.3% of 2 year OS and 51.2 months of median OS (P=.04).

CONCLUSION: Prognosis differed according to primary sites of noncutaneous melanoma. Based on our study, noncutaneous melanoma patients should be treated differently to improve survival outcome.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты